AFT Pharmaceuticals Ltd. 2023 AR2
The report reviews AFT Pharmaceuticals' operational, financial, and sustainability performance for the fiscal year ended March 31, 2023. The company achieved record operating revenue of $156.6 million, up 20% from the prior year, driven by strong product sales across all regions. Key milestones included registering Maxigesic Rapid Tablets with the US FDA and expanding its product portfolio to over 150 medicines. On sustainability, AFT introduced a Supplier Code of Conduct, achieved 99% diversion of packaging waste from landfills in its warehouses, and initiated preparations to report against the Aotearoa New Zealand Climate Standards.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2023
Type: AR2
Pages: 86
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report reviews AFT Pharmaceuticals' operational, financial, and sustainability performance for the fiscal year ended March 31, 2023. The company achieved record operating revenue of $156.6 million, up 20% from the prior year, driven by strong product sales across all regions. Key milestones included registering Maxigesic Rapid Tablets with the US FDA and expanding its product portfolio to over 150 medicines. On sustainability, AFT introduced a Supplier Code of Conduct, achieved 99% diversion of packaging waste from landfills in its warehouses, and initiated preparations to report against the Aotearoa New Zealand Climate Standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees